Get notified when IRD files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsRed Flags Detected
- Immediate Dilution of $1.52 Per Share (new) — New investors pay $2.09 per share while the as-adjusted net tangible book value is only $0.57, resulting in a 73% dilution relative to the offer price.
Opus Genetics prices $23M direct offering of 3.83M shares at $2.09 plus pre-funded warrants
Filed November 6, 2025 · ~1 min read
Key Changes
-
high
Opus Genetics is selling 3,827,751 shares at $2.09 each and 7,177,033 pre-funded warrants at $2.0899 each directly to institutional investors, for gross proceeds of about $23.0 million.
The Offering verify on EDGAR → -
high
The company estimates net proceeds of approximately $22.7 million, assuming full exercise of the pre-funded warrants and after offering expenses of about $0.3 million.
Use of Proceeds verify on EDGAR → -
high
Net proceeds will fund the LCA5 and BEST-1 gene therapy clinical programs, with the remainder for working capital and general corporate purposes.
Use of Proceeds verify on EDGAR →
3 more material changes behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.
Want to see a complete report first? Today's free report (FPS 10-K) is open in full — no account needed.
Partner
Trade IRD commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Sep 2, 2026 · How we verify